Furthermore, the study by Abdul-Al et al. raises concerns regarding the specificity of GPC-3 in patients with prior HCV-related liver damage, reporting that strong GPC-3 immunoreactivity was observed in 83% of biopsies from patients with high-grade chronic hepatitis C, in the absence of malignancy [28]. The gene discussed is GPC3; the disease is chronic hepatitis C virus infection.